PMID- 26778605
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20201209
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 180
DP  - 2016 Mar 2
TI  - Improvement of atopic dermatitis with topical application of Spirodela polyrhiza.
PG  - 12-7
LID - S0378-8741(16)30010-1 [pii]
LID - 10.1016/j.jep.2016.01.010 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Spirodela polyrhiza has been used as a 
      traditional remedy for the treatment of urticarial, acute nephritis, 
      inflammation, as well as skin disease. AIM OF STUDY: Atopic dermatitis (AD) is 
      characterized hyperplasia of skin lesion and increase of serum immunoglobulin E 
      (IgE) level. In this study, the topical effects of S. polyrhiza (SP) on 2, 
      4-dinitrochlorobenzene (DNCB)-induced AD mice model were investigated by several 
      experiments. MATERIALS AND METHODS: BALB/c mice were randomly divided into five 
      groups as NOR, CON, DEX, SP 1, and SP 100 groups (n=5, respectively). To induce 
      atopic dermatitis-like skin lesions, DNCB had been applied on shaved dorsal skin. 
      SP was topically treated to DNCB-induced mice as 1 and 100mg/mL concentrations. 
      Histological changes were showed by hematoxylin and eosin (H&E) staining and the 
      infiltration of mast cells was detected by toluidine blue staining. In addition, 
      the level of IgE and each cytokines were measured and expressions of inflammatory 
      signaling factors were analyzed by western blotting assay. RESULTS: SP treatment 
      improved a hyperplasia of epidermis and dermis in DNCB-induced AD-like skin 
      lesion. The infiltration of mast cells was also decreased by treatment of SP. In 
      addition, SP reduced the level of IgE in serum and attenuated the secretion of 
      cytokines such as interleukin (IL)-4, IL-6, and tumor necrosis factor (TNF)-alpha. 
      Treatment of SP also inhibited the expressions of pro-inflammatory mediators 
      including nuclear factor-kappaB (NF-kappaB), phosphor-IkappaB-alpha, and mitogen-activated 
      protein kinase (MAPK)s. CONCLUSIONS: From these data, we propose that SP 
      ameliorates AD via modulation of pro-inflammatory mediators. SP may have the 
      potential to be used as an alternative for treatment of AD.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Lee, Hye Ji
AU  - Lee HJ
AD  - Department of Convergence Korean Medical Science, College of Korean Medicine and 
      Institute of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of 
      Korea.
FAU - Kim, Mi Hye
AU  - Kim MH
AD  - Department of Convergence Korean Medical Science, College of Korean Medicine and 
      Institute of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of 
      Korea.
FAU - Choi, You Yeon
AU  - Choi YY
AD  - Department of Convergence Korean Medical Science, College of Korean Medicine and 
      Institute of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of 
      Korea.
FAU - Kim, Eun Hye
AU  - Kim EH
AD  - College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
FAU - Hong, Jongki
AU  - Hong J
AD  - College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
FAU - Kim, Kyuseok
AU  - Kim K
AD  - Department of Ophthalmology, Otorhinolaryngology and Dermatology of Korean 
      Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic 
      of Korea. Electronic address: kmdkskim@khu.ac.kr.
FAU - Yang, Woong Mo
AU  - Yang WM
AD  - Department of Convergence Korean Medical Science, College of Korean Medicine and 
      Institute of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of 
      Korea. Electronic address: wmyang@khu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160114
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dinitrochlorobenzene)
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Extracts)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - *Araceae
MH  - Dermatitis, Atopic/chemically induced/*drug therapy/metabolism/pathology
MH  - Dinitrochlorobenzene
MH  - Female
MH  - Immunoglobulin E/blood
MH  - Mast Cells/drug effects
MH  - Mice, Inbred BALB C
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - NF-KappaB Inhibitor alpha/metabolism
MH  - NF-kappa B/metabolism
MH  - Phytotherapy
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - Plant Leaves
MH  - Skin/drug effects/metabolism/pathology
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Cytokine
OT  - IgE
OT  - Spirodela polyrhiza
EDAT- 2016/01/19 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/19 06:00
PHST- 2015/09/11 00:00 [received]
PHST- 2016/01/13 00:00 [revised]
PHST- 2016/01/13 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0378-8741(16)30010-1 [pii]
AID - 10.1016/j.jep.2016.01.010 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2016 Mar 2;180:12-7. doi: 10.1016/j.jep.2016.01.010. Epub 2016 
      Jan 14.